Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -13.87 Million USD | -13.07% |
| 2021 | -11.5 Million USD | -16.01% |
| 2020 | -10.64 Million USD | 2.29% |
| 2019 | -10.81 Million USD | -97.32% |
| 2018 | -10.84 Million USD | 43.28% |
| 2017 | -13.14 Million USD | -117.05% |
| 2016 | -6.87 Million USD | 70.34% |
| 2015 | -21.31 Million USD | 45.96% |
| 2014 | -31.52 Million USD | 26.75% |
| 2013 | -38.03 Million USD | -37.33% |
| 2012 | -27.79 Million USD | -17.1% |
| 2011 | -24.85 Million USD | -164.72% |
| 2010 | -49.09 Million USD | 13.47% |
| 2009 | -35.84 Million USD | 1583.75% |
| 2008 | -2.47 Million USD | 93.62% |
| 2007 | -2.39 Million USD | -1441.24% |
| 2006 | -2.83 Million USD | -1.72% |
| 2005 | -2.97 Million USD | -2444.47% |
| 2004 | -1.14 Million USD | 111.09% |
| 2003 | -853.34 Thousand USD | 62.35% |
| 2002 | -2.22 Million USD | -241.08% |
| 2001 | 955.59 Thousand USD | -4.77% |
| 2000 | 1.66 Million USD | 137.75% |
| 1999 | -4.02 Million USD | 83.87% |
| 1998 | -27.19 Million USD | 3.26% |
| 1997 | -26.36 Million USD | -23.18% |
| 1996 | -22.96 Million USD | -94.63% |
| 1995 | -11.8 Million USD | 2.48% |
| 1994 | -12.1 Million USD | -44.05% |
| 1993 | -8.4 Million USD | -170.97% |
| 1992 | -3.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -2.96 Million USD | -150.13% |
| 2023 Q1 | -1.18 Million USD | 62.93% |
| 2023 Q3 | -2.1 Million USD | 29.04% |
| 2022 Q3 | -4.92 Million USD | -69.82% |
| 2022 Q4 | -3.19 Million USD | 35.08% |
| 2022 FY | - USD | -13.07% |
| 2022 Q1 | -2.98 Million USD | 18.02% |
| 2022 Q2 | -2.9 Million USD | 2.77% |
| 2021 Q3 | -2.42 Million USD | 9.28% |
| 2021 Q4 | -3.63 Million USD | -50.27% |
| 2021 Q2 | -2.66 Million USD | 19.83% |
| 2021 FY | - USD | -16.01% |
| 2021 Q1 | -3.33 Million USD | -18.9% |
| 2020 Q4 | -2.8 Million USD | 3.38% |
| 2020 FY | - USD | 2.29% |
| 2020 Q1 | -2.67 Million USD | 3.64% |
| 2020 Q2 | -2.32 Million USD | 13.1% |
| 2020 Q3 | -2.89 Million USD | -24.87% |
| 2019 Q1 | -2.39 Million USD | -103.91% |
| 2019 FY | - USD | -97.32% |
| 2019 Q4 | -2.77 Million USD | 10.13% |
| 2019 Q3 | -3.08 Million USD | -15.42% |
| 2019 Q2 | -2.67 Million USD | -11.5% |
| 2018 FY | - USD | 43.28% |
| 2018 Q4 | -1.17 Million USD | 68.09% |
| 2018 Q3 | -3.68 Million USD | -54.26% |
| 2018 Q2 | -2.38 Million USD | -232.35% |
| 2018 Q1 | 1.8 Million USD | 380.06% |
| 2017 Q3 | -2.32 Million USD | 50.93% |
| 2017 Q4 | -644.23 Thousand USD | 72.33% |
| 2017 Q2 | -4.74 Million USD | -154.29% |
| 2017 FY | - USD | -117.05% |
| 2017 Q1 | -1.86 Million USD | 45.68% |
| 2016 Q2 | -2 Million USD | 42.77% |
| 2016 FY | - USD | 70.34% |
| 2016 Q4 | -3.43 Million USD | -181.6% |
| 2016 Q3 | 4.21 Million USD | 309.76% |
| 2016 Q1 | -3.5 Million USD | 4.69% |
| 2015 FY | - USD | 45.96% |
| 2015 Q4 | -3.67 Million USD | -40.55% |
| 2015 Q2 | 493.78 Thousand USD | 106.32% |
| 2015 Q3 | -2.61 Million USD | -630.18% |
| 2015 Q1 | -7.81 Million USD | -64.98% |
| 2014 Q3 | -5.62 Million USD | 38.1% |
| 2014 Q2 | -9.08 Million USD | -5.91% |
| 2014 FY | - USD | 26.75% |
| 2014 Q1 | -8.57 Million USD | 34.28% |
| 2014 Q4 | -4.73 Million USD | 15.77% |
| 2013 FY | - USD | -37.33% |
| 2013 Q4 | -13.05 Million USD | -31.52% |
| 2013 Q2 | -8.29 Million USD | -19.77% |
| 2013 Q3 | -9.92 Million USD | -19.63% |
| 2013 Q1 | -6.92 Million USD | 1.42% |
| 2012 FY | - USD | -17.1% |
| 2012 Q4 | -7.02 Million USD | 22.52% |
| 2012 Q3 | -9.06 Million USD | -68.36% |
| 2012 Q2 | -5.38 Million USD | 14.86% |
| 2012 Q1 | -6.32 Million USD | 29.74% |
| 2011 Q2 | -2.17 Million USD | 11.79% |
| 2011 FY | - USD | -164.72% |
| 2011 Q4 | -9 Million USD | -40.16% |
| 2011 Q3 | -6.42 Million USD | -195.78% |
| 2011 Q1 | -2.46 Million USD | -248.24% |
| 2010 Q2 | 40.99 Million USD | 3234.36% |
| 2010 Q3 | -2.11 Million USD | -105.15% |
| 2010 Q4 | -707.12 Thousand USD | 66.5% |
| 2010 FY | - USD | 13.47% |
| 2010 Q1 | -1.3 Million USD | -68.44% |
| 2009 FY | - USD | 1583.75% |
| 2009 Q4 | -776.49 Thousand USD | -103.48% |
| 2009 Q2 | 12.9 Million USD | 864.8% |
| 2009 Q3 | 22.33 Million USD | 73.02% |
| 2009 Q1 | -1.68 Million USD | -160.51% |
| 2008 Q3 | -1.57 Million USD | -4666.65% |
| 2008 Q2 | -33.14 Thousand USD | -111.15% |
| 2008 Q1 | 297.35 Thousand USD | 100.87% |
| 2008 Q4 | -647.8 Thousand USD | 58.99% |
| 2008 FY | - USD | 93.62% |
| 2007 FY | - USD | -1441.24% |
| 2007 Q4 | -34.26 Million USD | -5319.95% |
| 2007 Q3 | 656.45 Thousand USD | 270.59% |
| 2007 Q2 | -384.81 Thousand USD | -2.65% |
| 2007 Q1 | -374.86 Thousand USD | 36.57% |
| 2006 Q1 | -343.7 Thousand USD | 48.97% |
| 2006 FY | - USD | -1.72% |
| 2006 Q3 | -1.02 Million USD | -275.95% |
| 2006 Q2 | -272.15 Thousand USD | 20.82% |
| 2006 Q4 | -590.98 Thousand USD | 42.24% |
| 2005 FY | - USD | -2444.47% |
| 2005 Q2 | -747.72 Thousand USD | -541.12% |
| 2005 Q4 | -673.57 Thousand USD | -2.94% |
| 2005 Q3 | -654.34 Thousand USD | 12.49% |
| 2005 Q1 | -116.62 Thousand USD | -117.95% |
| 2004 Q1 | -299.62 Thousand USD | 19.89% |
| 2004 Q2 | -239.86 Thousand USD | 19.95% |
| 2004 Q3 | -16.89 Thousand USD | 92.96% |
| 2004 Q4 | 649.88 Thousand USD | 3947.29% |
| 2004 FY | - USD | 111.09% |
| 2003 Q1 | -256.83 Thousand USD | -47.68% |
| 2003 FY | - USD | 62.35% |
| 2003 Q4 | -376.61 Thousand USD | -1.79% |
| 2003 Q3 | -371.01 Thousand USD | -342.18% |
| 2003 Q2 | 151.12 Thousand USD | 159.92% |
| 2002 Q2 | -675.99 Thousand USD | -14.66% |
| 2002 Q1 | -598.85 Thousand USD | -148.23% |
| 2002 FY | - USD | -241.08% |
| 2002 Q4 | -139.73 Thousand USD | 78.74% |
| 2002 Q3 | -809.88 Thousand USD | -19.78% |
| 2001 Q3 | 246.89 Thousand USD | -97.77% |
| 2001 FY | - USD | -4.77% |
| 2001 Q2 | 244.08 Thousand USD | 98.02% |
| 2001 Q1 | 129.87 Thousand USD | -69.84% |
| 2001 Q4 | 335.46 Thousand USD | 22357.77% |
| 2000 Q4 | 406.31 Thousand USD | 4.93% |
| 2000 Q2 | 528.43 Thousand USD | 1201.43% |
| 2000 Q1 | -47.97 Thousand USD | -117.13% |
| 2000 FY | - USD | 137.75% |
| 2000 Q3 | 387.23 Thousand USD | -26.72% |
| 1999 Q3 | -1.69 Million USD | -141.43% |
| 1999 Q2 | -700 Thousand USD | 53.33% |
| 1999 Q4 | 280 Thousand USD | 116.57% |
| 1999 Q1 | -1.5 Million USD | 88.72% |
| 1999 FY | - USD | 83.87% |
| 1998 Q4 | -13.29 Million USD | -564.74% |
| 1998 Q1 | -7.5 Million USD | 15.61% |
| 1998 FY | - USD | 3.26% |
| 1998 Q2 | -4.6 Million USD | 26.67% |
| 1998 Q3 | -2 Million USD | 63.64% |
| 1997 Q2 | -8.3 Million USD | -38.33% |
| 1997 Q4 | -8.88 Million USD | -53.23% |
| 1997 Q3 | -5.8 Million USD | 30.12% |
| 1997 FY | - USD | -23.18% |
| 1997 Q1 | -6 Million USD | -95.68% |
| 1996 FY | - USD | -94.63% |
| 1996 Q4 | -6.48 Million USD | 67.03% |
| 1996 Q3 | -6.7 Million USD | -55.0% |
| 1996 Q2 | -6 Million USD | -46.34% |
| 1996 Q1 | -4.1 Million USD | -17.14% |
| 1995 Q3 | -3 Million USD | -11.11% |
| 1995 Q4 | -3.5 Million USD | -16.67% |
| 1995 FY | - USD | 2.48% |
| 1995 Q2 | -2.7 Million USD | 10.0% |
| 1995 Q1 | -3 Million USD | 40.0% |
| 1994 FY | - USD | -44.05% |
| 1994 Q1 | -2.6 Million USD | -4.0% |
| 1994 Q2 | -2 Million USD | 23.08% |
| 1994 Q3 | -2.8 Million USD | -20.0% |
| 1994 Q4 | -3.8 Million USD | -108.33% |
| 1993 Q4 | -2.5 Million USD | -8.7% |
| 1993 Q2 | -2.1 Million USD | -50.0% |
| 1993 Q3 | -2.3 Million USD | -9.52% |
| 1993 FY | - USD | -170.97% |
| 1993 Q1 | -1.4 Million USD | -7.69% |
| 1992 FY | - USD | 0.0% |
| 1992 Q3 | -800 Thousand USD | 0.0% |
| 1992 Q4 | -1.3 Million USD | -62.5% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 56.2% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 65.241% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 72.863% |
| Azitra, Inc. | -10.67 Million USD | -30.0% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -69.622% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -102.194% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 51.486% |
| CEL-SCI Corporation | -27.56 Million USD | 49.656% |
| iBio, Inc. | -14.02 Million USD | 1.041% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 43.9% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 31.251% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 39.211% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -189.065% |
| NanoViricides, Inc. | -7.75 Million USD | -78.87% |
| Oragenics, Inc. | -20.87 Million USD | 33.54% |
| BiomX Inc. | -22.81 Million USD | 39.184% |
| BiomX Inc. | -22.81 Million USD | 39.184% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 219.089% |
| Palatin Technologies, Inc. | -29.03 Million USD | 52.206% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 60.45% |